Merck & Co., Inc. MRK
148.78
0.80
0.54%
as of 25 Sep
- Market cap
- $365.4B
- P/E
- 119×
Follow MRK
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Merck & Co., Inc. (MRK) P/B ratio
As of 25 September 2026, Merck & Co., Inc. (MRK) trades at a P/B ratio of 8.8×. Over the past ten years it has ranged from 2.8× (September 2015) to 9.2× (August 2026); the current reading is higher than 99% of that period. That is above the Drug Manufacturers General industry median of 5.0× and above the Healthcare sector median of 2.5×.
P/B ratio, daily
Annual
| Period | P/B ratio | Change |
|---|---|---|
| FY2025 | 5.0× | (7.93%) |
| FY2024 | 5.4× | (28.84%) |
| FY2023 | 7.6× | 24.94% |
| FY2022 | 6.1× | 20.55% |
| FY2021 | 5.1× | (34.80%) |
| FY2020 | 7.8× | (9.20%) |
| FY2019 | 8.6× | 18.48% |
| FY2018 | 7.2× | 70.54% |
| FY2017 | 4.2× | 7.57% |
| FY2016 | 3.9× | 24.24% |
Quarterly
| Period | P/B ratio | Change |
|---|---|---|
| Jun 2026 | 7.6× | 16.77% |
| Mar 2026 | 6.5× | 29.45% |
| Dec 2025 | 5.0× | 23.97% |
| Sep 2025 | 4.0× | (0.39%) |
| 42 more quarters | Free account |
Against its own ten years
Low 2.8×
High 9.2×
Ten-year median
5.6×
Current reading's percentile
99
P/B ratio against peers
| Company | P/B ratio |
|---|---|
| ABBV AbbVie Inc. compare | n/m |
| PFE Pfizer Inc. compare | 1.9× |
| NVO Novo Nordisk A/S compare | 5.0× |
| AZN AstraZeneca PLC compare | 5.1× |
| NVS Novartis AG compare | 6.6× |
| JNJ Johnson & Johnson compare | 7.7× |
| MRK Merck & Co., Inc. | 8.8× |
| GILD Gilead Sciences, Inc. compare | 16.0× |
| AMGN Amgen Inc. compare | 19.2× |
| Drug Manufacturers General industry median | 5.0× |
| Healthcare sector median | 2.5× |
| Market median | 1.8× |
What P/B ratio is
Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.
Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))
More on MRK
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement